Noel Donnelly
Finanzdirektor/CFO bei PEPGEN INC.
Vermögen: - $ am 30.04.2024
Profil
Noel Donnelly is currently the Chief Financial Officer at PepGen Inc. He previously worked as the Chief Financial Officer at EIP Pharma, Inc. from 2019 to 2021.
He holds an MBA from Babson College and an undergraduate degree from the University of Massachusetts Lowell.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
PEPGEN INC.
-.--% | 31.03.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Noel Donnelly
| Unternehmen | Position | Beginn |
|---|---|---|
| PEPGEN INC. | Finanzdirektor/CFO | 01.10.2021 |
Ehemalige bekannte Positionen von Noel Donnelly
| Unternehmen | Position | Ende |
|---|---|---|
EIP Pharma, Inc.
 EIP Pharma, Inc. BiotechnologyHealth Technology EIP Pharma, Inc. engages in the research and development of therapeutic drugs for the central nervous system disorders. It focuses on neflamapimod, which is a clinical-stage oral investigational drug for the treatment of brain diseases such as Alzheimer?s disease and for non-brain disorders including rheumatoid arthritis. The company was founded by John Alam and Sylvie Louise Gregorie and is headquartered in Cambridge, MA. | Finanzdirektor/CFO | 01.10.2021 |
Ausbildung von Noel Donnelly
| Babson College | Masters Business Admin |
| University of Massachusetts Lowell | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| PEPGEN INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
EIP Pharma, Inc.
EIP Pharma, Inc. BiotechnologyHealth Technology EIP Pharma, Inc. engages in the research and development of therapeutic drugs for the central nervous system disorders. It focuses on neflamapimod, which is a clinical-stage oral investigational drug for the treatment of brain diseases such as Alzheimer?s disease and for non-brain disorders including rheumatoid arthritis. The company was founded by John Alam and Sylvie Louise Gregorie and is headquartered in Cambridge, MA. | Health Technology |
